Specifically, taxane and platinum‐based chemotherapeutics stimulate tumor‐specific CD8 T cell responses,40, 41 which class I HDAC inhibition might elaborate by improving tumor‐specific T cell function and impairing intratumoral suppressive networks. The gene discussed is CD8A; the disease is neoplasm.